BeOne Medicines Ltd ADR
ONC: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| <r$ | LOCK|$^ | LOCK|PgT%VJ |
BeOne Earnings: Brukinsa Sales Strong While Margin Expands; Fair Value Up 12% as Guidance Raised
BeOne's third-quarter 2026 revenue grew 34% year on year to USD 1.9 billion, while operating margin increased 260 basis points sequentially to 22%. Growth was driven by Brukinsa sales, its flagship product, which continues to gain market share.
